Merck & Company Inc (MRK)vsSilence Therapeutics PLC (SLN)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
SLN
Silence Therapeutics PLC
$13.02
-2.18%
HEALTHCARE · Cap: $906.83M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 10824127% more annual revenue ($66.57B vs $615,000). MRK leads profitability with a 4.8% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 36/100 (F).
MRK
Hold36
out of 100
Grade: F
SLN
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Intrinsic value data unavailable for SLN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Revenue surging 197.2% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Trading at 16.1x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : SLN
The strongest argument for SLN centers on Revenue Growth, Debt/Equity. Revenue growth of 197.2% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : SLN
The primary concerns for SLN are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
MRK profiles as a value stock while SLN is a hypergrowth play — different risk/reward profiles.
SLN carries more volatility with a beta of 1.44 — expect wider price swings.
SLN is growing revenue faster at 197.2% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (36/100 vs 27/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Silence Therapeutics PLC
HEALTHCARE · BIOTECHNOLOGY · USA
Silence Therapeutics plc, a biotechnology company, is focused on the discovery and development of new ribonucleic acid (RNA) therapies in hematology, cardiovascular, and other rare and metabolic indications. The company is headquartered in London, the United Kingdom.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?